CCox

[CCox @CCoxLaw]

Criticism Of FDA Citizen Petitions Is Often Misguided https://t.co/WIxWqwtEIB

[DonnaYoungDC @DonnaYoungDC]

Donald Trump's science office is a ghost town
https://t.co/xoi1ROFB5d @CBSNews #science #STEM #pharma #biotech

[AtlanticLIVE @AtlanticLIVE]

Phil Nickleson of Momenta Pharmaceuticals: We're witnessing the birth of a new industry here, with that comes uncertainty #ATLPoliticsPolicy

[CCox @CCoxLaw]

Momenta: increased certainty from SCOTUS benefits everyone #Biosimilars #ATLPoliticsPolicy

[CCox @CCoxLaw]

Great convo this morning @AtlanticLIVE @BiosimsCouncil for more coverage on all things #biosimilars follow @Big_Molecule #ATLPoliticsPolicy

[AtlanticLIVE @AtlanticLIVE]

Momenta Pharmaceuticals' Phil Nickson points out the competition makes people run faster—same is true of drug industry #ATLPoliticsPolicy

[AtlanticLIVE @AtlanticLIVE]

Are there safety concerns with these products? @LillyPad's Bruce Artim expects similar certainty as those FDA approved #ATLPoliticsPolicy

[CCox @CCoxLaw]

Eli Lilly and Momenta expect significant savings and Momenta thinks #biosimilars competition will spur more innovation #ATLPoliticsPolicy

[CCox @CCoxLaw]

Momenta rep: safety is an important issue and we haven't seen any data that #biosimilars are not as safe as biologics #ATLPoliticsPolicy

[CCox @CCoxLaw]

Eli Lilly rep: development time cuts substantially into patent exclusivity #ATLPoliticsPolicy #Biosimilars

[CCox @CCoxLaw]

Eli Lilly rep: BPCIA wasn't adequately fleshed out in Congress #ATLPoliticsPolicy #Biosimilars

[CCox @CCoxLaw]

Momenta: alt remedies are available when you don't dance and various options are available to the parties #biosimilars #ATLPoliticsPolicy

[CCox @CCoxLaw]

Representative from Eli Lilly on #patentdance: drafter's expectation was that information sharing is mandatory

[CCox @CCoxLaw]

Talking Amgen v. Sandoz with #ATLPoliticsPolicy #Biosimilars #patentdance

[CCox @CCoxLaw]

Summary of Sandoz’s Response and Reply Brief in Sandoz v. Amgen https://t.co/2mbTE0Iorq

[DonnaYoungDC @DonnaYoungDC]

Apobiologix Van Lieshout: Trying to make it as easy as possible needs to be true goal of new admin
#ATLPoliticsPolicy #biosimilars #FDA

[CCox @CCoxLaw]

.@DrLen expects postmarketing studies to be critical to build confidence with #biosimilars and interchangeability #ATLPoliticsPolicy

[CCox @CCoxLaw]

.@DrLen @AmericanCancer doesn't take a position on #biosimilar naming, but conventions are important for traceability

[CCox @CCoxLaw]

Subcommittee goal will be more efficient biosimilar pathway and more products on market @michaelcburgess #ATLPoliticsPolicy #biosimilars

[CCox @CCoxLaw]

On FDA reauthorization, @michaelcburgess wants to see more predictability and biosimilar approvals, will look at staffing